ART Advanced Research Technologies Secures First Direct Sale in Europe for its New Optix MX2 Molecular Imaging System
14 December 2007 - 12:56AM
Marketwired
MONTREAL, CANADA (TSX: ARA), a Canadian medical device company
and a leader in optical molecular imaging products for the
healthcare and pharmaceutical industries, is pleased to announce
that it has received an order from a European client for its
recently released preclinical optical molecular imaging system, the
Optix� MX2. The unit is expected to be shipped before the end of
the year. This represents the first Optix unit sold in Europe by
ART under its new commercial strategy.
"In Europe, as in the rest of the world, optical molecular
imaging is leading the way when it comes to reducing drug
development costs and helping to get new treatments to market
faster," stated Sebastien Gignac, President and CEO of ART. "The
interest from European research centres in our Optix MX2 system has
been palpable, especially since Rik van Heijningen, Director of
European Commercial Operations, has come on board to implement our
new direct commercialization strategy in Europe. This sale to an
important cancer and cardiovascular disease research centre in
Europe confirms this interest", added Mr. Gignac.
"ART has the most sensitive optical imaging system in the
market, and we believe that researchers are realizing the real
value of the data set they are acquiring through the Optix system,
which is enhancing their results considerably. In the case of new
cancer therapies being developed, ART's technology can allow
researchers to non-invasively see changes on the molecular level
long before they become visible by anatomic imaging," concluded
Dino DiCamillo, ART's Vice President, Global Sales & Marketing
for Preclinical Imaging.
About the Optix� system
Based on time-domain technology, which allows measurement of the
light's time of arrival, the Optix� in vivo optical molecular
imaging device is the most sensitive optical imager commercially
available on the preclinical market, allowing for detection of
lower concentrations of signals deeper inside the body. Unique to
the Optix system is the ability to recover fluorescence lifetime,
which can be used to separate and quantify probe distributions
depending on their respective biochemical environment. Also part of
the Optix product offering is a new CT fusion software package
allowing researchers to export the scan obtained using Optix in
DICOM format, and fuse it with microCT for a full 3D anatomical
reference.
About ART
ART Advanced Research Technologies Inc. is a leader in molecular
imaging products for the healthcare and pharmaceutical industries.
ART has developed products in medical imaging, medical diagnostics,
disease research, and drug discovery with the goal of bringing new
and better treatments to patients faster. The Optix� optical
molecular imaging system, designed for monitoring physiological
changes in living systems at the preclinical study phases of new
drugs, is distributed directly by ART in North America and Europe
and is used by industry and academic leaders worldwide. The
SoftScan� optical breast imaging device is designed to improve the
diagnosis and treatment of breast cancer. ART is commercializing
the SoftScan optical medical imaging device via a global strategic
alliance with GE Healthcare, a world leader in mammography and
imaging. Finally, the Fenestra� line of molecular imaging contrast
products provide image enhancement for a wide range of preclinical
Micro CT applications allowing scientists to see greater detail in
their imaging studies, with potential extension into other major
imaging modalities. The distribution of the Fenestra line of
imaging contrast agents is made through GE Healthcare Bio-Science
KK in Japan and is sold directly by the Company in the rest of the
world. ART's shares are listed on the TSX under the ticker symbol
ARA. For more information on ART, visit our website at www.art.ca
.
This press release may contain forward-looking statements
subject to risks and uncertainties that would cause actual events
to differ materially from expectations. These risks and
uncertainties are described in the most recent Annual Information
Form and the financial statements for the year ended December 31,
2006, available on SEDAR (www.sedar.com).
Contacts: ART Advanced Research Technologies Inc. Jacques Bedard
Chief Financial Officer 514-832-0777 jbedard@art.ca ART Advanced
Research Technologies Inc. Dino DiCamillo, Vice President Global
Sales & Marketing for Preclinical Imaging 514-832-0777
www.art.ca
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jul 2023 to Jul 2024